Comunicati Stampa
Scienza e Tecnologia

CELLINK launches the S.NEST, a high-throughput microbioreactor with real-time monitoring to ensure maximum cell growth and streamlined workflows

CLD researchers looking to streamline upscaling and expansion workflows, which previously required weeks to complete, are sure to embrace the S.NEST's unique suspension culturing nourished by a continuous supply of oxygen. As part of CYTENA's extensive portfolio of single-cell instruments, the S.NEST will make highly efficient cell culturing results accessible to laboratories around the world. CLD researchers looking to streamline upscaling and expansion workflows, which previously required...
STOCKHOLM, (informazione.news - comunicati stampa - scienza e tecnologia)

CLD researchers looking to streamline upscaling and expansion workflows, which previously required weeks to complete, are sure to embrace the S.NEST's unique suspension culturing nourished by a continuous supply of oxygen. As part of CYTENA's extensive portfolio of single-cell instruments, the S.NEST will make highly efficient cell culturing results accessible to laboratories around the world.

says Charles Tsai , PhD, CEO CYTENA Bioprocess Solutions.

Phone (US): +1 (650) 515 5566

Phone (Sweden): +46 73 267 00 00

  E-mail: eg@cellink.com  

Phone (Sweden): +46 709-91 86 04 

E-mail: gd@cellink.com

Founded in 2016, CELLINK is the leading bioconvergence company in the world that provides technologies, products and services to create, understand and master biology. With a focus on the application areas of bioprinting, multiomics, cell line development, and diagnostics, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. CELLINK's products are trusted by more than 2,000 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 1,700 publications. CELLINK is creating the future of medicine. CELLINK is listed on the Nasdaq the Stockholm under CLNK B. www.cellink.com  

CELLINK has initiated the process to change name from CELLINK to BICO to better reflect the company's strategy, bio convergence agenda and market position. Read more about the process for the name change in the press release that was sent out on July 7, 2021 , www.cellink.com/investors/press-release s  

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/cellink-ab/r/cellink-launches-the-s-nest--a-high-throughput-microbioreactor-with-real-time-monitoring-to-ensure-m,c3386678

The following files are available for download:

 

Ufficio Stampa
 PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
Allegati
Non disponibili